Artio Medical Announces Successful First Human Use of the Amplifi Vein Dilation System

First-of-its-kind medical device aims to improve vascular access for hemodialysis patients

Prairie Village, KS – January 27, 2021 – Artio Medical, Inc., a medical device company developing innovative products for the peripheral vascular, neurovascular, and structural heart markets, announced today that it has successfully completed the first human use of its AmplifiTM Vein Dilation System. The first clinical procedure was performed by Adrian Ebner, MD, the Head of the Cardiovascular Department at Sanatorio Italiano Hospital in Asuncion, Paraguay.

An arteriovenous fistula (AVF) is the preferred type of vascular access for most end-stage renal disease patients requiring hemodialysis, and clinical research has shown that AVFs last longer and have fewer complications than other forms of access.1 Currently, about 35% of U.S. hemodialysis patients are ineligible to receive an AVF, predominantly due to small vein diameters.2 Of those patients who are eligible, more than 50% of AVFs fail to mature without additional procedures, and many of these sites are abandoned prior to routine use.2 Studies suggest baseline vein diameter may play an important role in eligibility for AVF surgery, and in achieving AVF maturation and use.3

“Vascular access is a constant challenge for end stage renal disease patients who depend on hemodialysis treatment. Most patients are plagued with interrupted or delayed care due to repeated access site failures and require additional procedures and surgeries to maintain vascular access,” commented Dr. Ebner. “Many also frequently experience access site complications, often resulting in hospitalization and the need for additional care. I am pleased to be a part of the first human use for the Amplifi system. This is the first technology that seeks to address these challenges by proactively preparing patient’s veins for AVF creation.”

Artio Medical’s Amplifi Vein Dilation System is designed to stimulate arm vein enlargement in hemodialysis patients using rapid, non-pulsatile blood flow. The innovative system is designed for percutaneous placement and includes a wearable, external blood pump, inflow and outflow catheters, and a controller. The Amplifi system is used for 7 to 10 days and removed completely during AVF creation.

“I believe this device has the potential to change the standard of care for hemodialysis patients, allowing more patients to be eligible for AVF surgery and reducing the risk of AVF failure and abandonment,” continued Dr. Ebner. “The degree of vein dilation we observed during the treatment period for the first patient was remarkable, and the AVF made with the treated vein matured very rapidly.”

“Artio Medical is committed to developing novel devices that have the potential to provide better patient outcomes,” stated F. Nicholas Franano, MD, President and CEO of Artio Medical. “Many thanks to Dr. Ebner and the entire clinical team at Sanatorio Italiano for helping Artio reach this important milestone. We look forward to sharing the results of our first clinical experience with the Amplifi system.”

Artio Medical acquired the first-of-its-kind vein dilation technology through the acquisition of Flow Forward Medical, Inc. in June 2020. The Amplifi Vein Dilation System aims to address common issues related to vascular access site creation and maintenance for the 2.3 million patients worldwide with end-stage renal disease who require hemodialysis.2 Artio expects to complete the first-in-human clinical study in the first half of 2021.


About Artio Medical

Artio Medical is a medical device company committed to developing innovative endovascular products for the treatment of peripheral vascular, neurovascular, and structural heart diseases. Artio’s products are designed to provide precision placement, immediate occlusion, and rapid sealing of arteries, veins, saccular aneurysms, and other blood-containing structures. For more information, please visit

About the AmplifiTM Vein Dilation System

Patients with end-stage renal disease have a complete loss of kidney function and usually require routine hemodialysis. Creating and maintaining a suitable vascular access site is one of the most difficult and expensive aspects of hemodialysis. The National Kidney Foundation and Centers for Medicare and Medicaid Services agree that an arteriovenous fistula (AVF) is the preferred form of vascular access. The AmplifiTM Vein Dilation System is a wearable, external blood pump system designed to stimulate arm vein enlargement in hemodialysis patients using rapid, non-pulsatile blood flow that is used for 7 to 10 days and removed during AVF surgery. The Amplifi system aims to make more patients eligible to receive an AVF and to increase successful maturation after AVF creation surgery.


Company Contact:
Jenny Martin
Director of Marketing and Operations
Artio Medical, Inc.

Media Contact:
Katie Arnold
SPRIG Consulting, LLC


1 Hemodialysis National Institute of Diabetes and Digestive and Kidney Disease,

2 United States Renal Data System (USRDS) End Stage Renal Disease Annual Data Report. 2018.

3 Robbin M., et al. “Arteriovenous fistula development in the first 6 weeks after creation”. Radiology. Vol. 279: No. 2 – May 2016